Dan Pollyea, MD, Discusses Venetoclax For Patients With AML Harboring IDH Mutations

Video

Pollyea discussed the rationale behind a study of venetoclax and azacitidine for patients with acute myeloid leukemia with IDH mutations

In an interview with CancerNetwork®, Daniel A. Pollyea, MD of the University of Colorado Cancer Center, discussed the rationale behind a study of venetoclax (Venclexta) and azacitidine (Vidaza) for patients with acute myeloid leukemia with IDH mutations.

Transcription:

What this study explores is the particular subset of patients who have IDH mutation[s]. We’ve known from the very beginning of the clinical experience with venetoclax that IDH patients respond even better than the patients who don’t have an IDH mutation. So this study really is the largest look at that, with an opportunity to look at several 100 patients with IDH mutations and what their outcomes were with venetoclax-based regimens, and then look at the placebo group, as well, that didn’t receive venetoclax. So, I think this helps answer a lot of questions that folks have had regarding to what degree this impacts outcomes, and it’s a pretty large degree of response.

Related Videos
Common adverse effects following treatment with lenvatinib plus pembrolizumab in the phase 3 CLEAR study include diarrhea, hypertension, and fatigue, according to Thomas E. Hutson, DO, PharmD, FACP.
Lenvatinib in combination with pembrolizumab appears to raise no new safety signals in patients with advanced clear cell renal cell carcinoma after 4 years of follow-up in the phase 3 CLEAR study.
According to Thomas E. Hutson, DO, PharmD, FACP, 4-year follow-up data from the phase 3 CLEAR study confirm the maintained benefits of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Rana R. McKay, MD discusses presentations of interest that were presented at the 2023 Kidney Cancer Research Summit, including a discussion on how PET imaging may identify which patients with renal cell carcinoma may respond to immunotherapy.
Mikkael A. Sekeres, MD, discusses how data from the phase 3 QuANTUM-First trial may advance the treatment field for patients with newly diagnosed FLT3-ITD–positive acute myeloid leukemia.
A better understanding of tumor biology may be necessary for identifying novel non-immunotherapy–based therapeutic strategies for patients with renal cell carcinoma, according to Rana R. McKay, MD.
Probiotics and other agents targeting fatty acid oxidation are also under evaluation as treatment options for patients with renal cell carcinoma, according to Rana R. McKay, MD.
Other angiogenic agents are also under investigation in renal cell carcinoma, according to Rana McKay, MD, who indicates it will be interesting to see how they compare with belzutifan.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.